Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Earl, Helena M"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
    Autorzy:
    Abraham JE; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
    Hiller L; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. .
    Dorling L; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. .
    Vallier AL; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
    Dunn J; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. .
    Bowden S; Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. .
    Ingle S; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. .
    Jones L; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
    Hardy R; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. .
    Twelves C; Level 4, Leeds Institute of Cancer and Pathology and Leeds Experimental Cancer Medical Centre, St James Institute of Oncology, Beckett Street, Leeds, LS9 7TF, UK. .
    Poole CJ; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. .
    Pharoah PD; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. .
    Caldas C; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. .
    Earl HM; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
    Pokaż więcej
    Źródło:
    BMC medicine [BMC Med] 2015 Dec 29; Vol. 13, pp. 306. Date of Electronic Publication: 2015 Dec 29.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents/*adverse effects
    Breast Neoplasms/*drug therapy
    Chemotherapy, Adjuvant/*adverse effects
    Antineoplastic Agents/therapeutic use ; Breast Neoplasms/mortality ; Case-Control Studies ; Chemotherapy, Adjuvant/methods ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Prognosis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
    Autorzy:
    Earl, Helena M
    Hiller, Louise
    Howard, Helen C
    Dunn, Janet A
    Young, Jennie
    Bowden, Sarah J
    McDermaid, Michelle
    Waterhouse, Anna K
    Wilson, Gregory
    Agrawal, Rajiv
    O'Reilly, Susan
    Bowman, Angela
    Ritchie, Diana M
    Goodman, Andrew
    Hickish, Tamas
    McAdam, Karen
    Cameron, David
    Dodwell, David
    Rea, Daniel W
    Caldas, Carlos
    Pokaż więcej
    Źródło:
    Lancet Oncology. Jun2017, Vol. 18 Issue 6, p755-769. 15p.
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
    Autorzy:
    Clamp, Andrew R (AUTHOR)
    James, Elizabeth C (AUTHOR)
    McNeish, Iain A (AUTHOR)
    Dean, Andrew (AUTHOR)
    Kim, Jae-Weon (AUTHOR)
    O'Donnell, Dearbhaile M (AUTHOR)
    Hook, Jane (AUTHOR)
    Coyle, Christopher (AUTHOR)
    Blagden, Sarah (AUTHOR)
    Brenton, James D (AUTHOR)
    Naik, Raj (AUTHOR)
    Perren, Tim (AUTHOR)
    Sundar, Sudha (AUTHOR)
    Cook, Adrian D (AUTHOR)
    Gopalakrishnan, Gosala S (AUTHOR)
    Gabra, Hani (AUTHOR)
    Lord, Rosemary (AUTHOR)
    Dark, Graham (AUTHOR)
    Earl, Helena M (AUTHOR)
    Hall, Marcia (AUTHOR)
    Pokaż więcej
    Temat:
    PROGRESSION-free survival
    MEDICAL Research Council (Great Britain)
    CANCER Research UK (Organization)
    FALLOPIAN tubes
    SURVIVAL analysis (Biometry)
    OVARIAN epithelial cancer
    CYTOREDUCTIVE surgery
    CANCER chemotherapy
    ANTINEOPLASTIC agents
    CANCER
    COMBINED modality therapy
    GYNECOLOGIC surgery
    FEMALE reproductive organ tumors
    PERIPHERAL neuropathy
    OVARIAN tumors
    PACLITAXEL
    TUMOR classification
    WHITE people
    PERITONEUM tumors
    RANDOMIZED controlled trials
    PROPORTIONAL hazards models
    CARBOPLATIN
    TUMOR grading
    Źródło:
    Lancet. Dec2019, Vol. 394 Issue 10214, p2084-2095. 12p.
    Terminy geograficzne:
    IRELAND
    Czasopismo naukowe
    Szczegóły
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies